HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

Summary

This study involves imaging participants' brains using MRI. The goal is to develop a high-resolution, high-sensitivity imaging tool, hyperpolarized xenon functional brain magnetic resonance imaging, which can provide more sensitive measurement of brain function, facilitating the development of drugs for more successful treatment of Alzheimer's disease.

Conditions

• Alzheimer Disease

Interventions

OTHER

Traditional Proton fMRI

Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).

OTHER

Hyperpolarized Xenon-129 fMRI

HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.

DRUG

Hyperpolarized Xenon-129

Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.

DEVICE

1H-129Xe Dual-Tuned Quadrature Head Coil

A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.

Sponsors & Collaborators

• Lakehead University

  collaborator OTHER

• Thunder Bay Regional Health Sciences Centre

  collaborator OTHER

• Thunder Bay Regional Health Research Institute

  lead OTHER

Principal Investigators

• Mitchell Albert, Ph.D. · Thunder Bay Regional Health Research Institute

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2016-06-27

Primary Completion

2022-04-19

Completion

2022-04-19

Countries

• Canada

Study Locations